Publication: Optimizing Glioblastoma Temozolomide chemotherapy employing Lentiviral-based anti-MGMT shRNA technology
Optimizing Glioblastoma Temozolomide chemotherapy employing Lentiviral-based anti-MGMT shRNA technology
Date
Date
Date
Citations
Viel, T., Monfared, P., Schelhaas, S., Fricke, I. B., Kuhlmann, M. T., Fraefel, C., & Jacobs, A. H. (2013). Optimizing Glioblastoma Temozolomide chemotherapy employing Lentiviral-based anti-MGMT shRNA technology. Molecular Therapy, 21(3), 570–579. https://doi.org/10.1038/mt.2012.278
Abstract
Abstract
Abstract
Despite treatments combining surgery, radiation-, and chemotherapy, patients affected by glioblastoma (GBM) have a limited prognosis. Addition of temozolomide (TMZ) to radiation therapy is the standard therapy in clinical application, but effectiveness of TMZ is limited by the tumor's overexpression of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). The goal of this study was to use the highly specific and efficient RNA interference (RNAi) pathway to modulate MGMT expression to increase TMZ efficiency in chemothe
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Viel, Thomas
- Monfared, Parisa
- Schelhaas, Sonja
- Fricke, Inga B
- Kuhlmann, Michael T
- Fraefel, Cornel
- Jacobs, Andreas H
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Downloads
Views
Citations
Viel, T., Monfared, P., Schelhaas, S., Fricke, I. B., Kuhlmann, M. T., Fraefel, C., & Jacobs, A. H. (2013). Optimizing Glioblastoma Temozolomide chemotherapy employing Lentiviral-based anti-MGMT shRNA technology. Molecular Therapy, 21(3), 570–579. https://doi.org/10.1038/mt.2012.278
